Celcuity

Celcuity Employees

13 people indexed:

Bernhard Lampert, PhD

VP of Pharmaceutical Development

gnjg7nq6.92n@9gx92gs6.k13 Sign up to see email

37vk7w49.g1s@gnj0n7wg.zj1 Sign up to see email
Brian Sullivan

CEO and Co-founder

jq91431fh@7qz7975f.hgh Sign up to see email

xpj70081d@7109795z.18r Sign up to see email
Charlotte Moser, MD, PhD, MBA

SVP of Clinical Development

fkq332.40.v30.0q9@37836881.2z4 Sign up to see email

53vznk.0v.gk9.w3n@f8nq3j8n.62n Sign up to see email
David Bridge

VP of Quality Assurance and Process Development

6h1vs2x@j2fxfpa0.463 Sign up to see email

200nzzf@7z1x7560.8nw Sign up to see email
Eldon Mayer

Chief Commercial Officer

6kpn9k@z7vsk71d.pvq Sign up to see email

63s0p1@47035hh2.v3n Sign up to see email
Fred Kerwood

VP of Program Management

91b275vp@9x159vh7.s65 Sign up to see email

938a1b96@hbsp2978.vp6 Sign up to see email
Igor Gorbatchevsky, MD

Chief Medical Officer

0pw0xzq4qfw57x.5j@78749x23.883 Sign up to see email

z0j2q802p93p2j.84@3f1z4zz7.fn5 Sign up to see email
John R. MacDonald, PhD

SVP of R&D

76.k2zzxvvsv.4bx@4x1w66v8.4g3 Sign up to see email

67.5fq9gg92f.96x@g29999wg.q37 Sign up to see email
Lance Laing, PhD

Chief Science Officer and Co-founder

vv4937.777@03x2vw91.90s Sign up to see email

fwsj38.1z1@b8w5143r.5k8 Sign up to see email
Nadene Zack

VP Clinical Operations

43x11@j0r48s3s.017 Sign up to see email

7861w@wbqg4gs6.b5h Sign up to see email
Pratima Nayak, MD

VP of Medical Affairs

51bf46.s8@bx75wzs2.jjb Sign up to see email

r866xx.qv@9s39g6b9.9bw Sign up to see email
Sunni Miller

VP of Regulatory Affairs

pfpja2f@dv167xh6.zvh Sign up to see email

w8hpf74@n46jak5w.496 Sign up to see email
Vicky Hahne

CFO

5qj65x@r5sq8b02.jfs Sign up to see email

bz9539@sg09r176.sgr Sign up to see email

Celcuity Company Information

Celcuity is a clinical-stage biotechnology company that specializes in discovering previously undetectable cancer drivers and developing targeted therapies to treat them. The company’s lead drug candidate, gedatolisib, is a dual PI3K – mTOR inhibitor, which is currently under clinical trials for breast cancer and prostate cancer. Celcuity employs a third-generation cellular analysis platform that can identify complex oncogenic activities that traditional molecular tests cannot detect. This platform enables the company to perform comparative analyses using live patient tumor cells, thereby revealing opportunities for the development of first-in-class drugs. Additionally, Celcuity offers an Expanded Access Program for patients who have previously participated in a clinical trial for an investigational medicine that is no longer open.

Report inaccurate information